FCGR3B — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL13917176	1.00	1/20
SCHEMBL13421296	0.96	1/20
SCHEMBL13917185	0.89	1/20
SCHEMBL13921798	0.84	1/20
SCHEMBL13420987	0.82	1/20
SCHEMBL13420936	0.82	1/20
SCHEMBL13421092	0.81	1/20
SCHEMBL13917179	0.81	1/20
SCHEMBL13421360	0.81	1/20
SCHEMBL13421062	0.80	1/20
SCHEMBL13917183	0.80	1/20
SCHEMBL13917186	0.80	1/20
SCHEMBL13917188	0.80	1/20
SCHEMBL3200004	0.80	1/20
SCHEMBL13921832	0.80	1/20
SCHEMBL13420995	0.79	1/20
SCHEMBL13921837	0.78	1/20
SCHEMBL13421038	0.78	1/20
SCHEMBL13921814	0.77	1/20
SCHEMBL13421029	0.77	1/20

Clinical trials — most relevant to FCGR3B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)	PHASE4	COMPLETED
Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients	PHASE2/PHASE3	COMPLETED
Allergic Rhinitis, Immunotherapy and Vitamin d	PHASE2/PHASE3	UNKNOWN
Rituximab Maintenance Versus Observation After First-line Immunochemotherapy by FCR in Older Patients With Chronic Lymphocytic Leukemia	PHASE3	COMPLETED
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma	PHASE2	COMPLETED
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide	PHASE1/PHASE2	COMPLETED
Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment	PHASE2	UNKNOWN
Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations	PHASE2	NOT_YET_RECRUITING
Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma	PHASE2	COMPLETED
Post IVIG Medication in Children With Immune Thrombocytopenia	PHASE1	UNKNOWN
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma	PHASE1	ACTIVE_NOT_RECRUITING
Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma	PHASE1	COMPLETED
Preventive IVIG Therapy for Congenital Heart Block	EARLY_PHASE1	COMPLETED
Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte Myelin Protein Antibody Disease, and Multiple Sclerosis.	nan	RECRUITING
Subclass of Donor-specific Antibody as a Risk Factor of Antibody Mediated Rejection in Renal Transplantation	nan	COMPLETED
Does CMV Induced Changes in NK Lymphocyte Biology Influence the Effectiveness of Antibody Therapy Used to Treat B Cell Lymphoproliferative Diseases?	nan	UNKNOWN
Prognostic Value of CD64 Marker for Patients in Intensive Care Unit	nan	UNKNOWN
Role of the Neonatal Fc Receptor for IgG in the Pathophysiology of Lupus	nan	COMPLETED
Comparison Between Methyl Prednisolone and Intravenous Dexamethazone in Severe Immune Thrombocytopenic Purpra	nan	UNKNOWN
FGL2/Fibroleukin and Hepatitis C Virus Recurrence Post Liver Transplantation	nan	UNKNOWN
sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN	nan	UNKNOWN
Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer	nan	RECRUITING
Contribution of Nasal IgE Production to the Boost of Systemic Allergen-specific IgE Upon Nasal Allergen Contact	nan	RECRUITING
Kinetics of Nasal Cytokine Responses to Mechanical Stimulation	nan	COMPLETED
Obinutuzumab in the Management of Idiopathic Membranous Nephropathy	nan	UNKNOWN
Applying Systems Immunology to the Search for Personalized Biomarkers of Clinical Efficacy	nan	COMPLETED
Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) Gene Single-nucleotide Polymorphism in Primary Immune Thrombocytopenic Purpura in Children	nan	NOT_YET_RECRUITING
Role of LILRA3 in Ankylosing Spondylitis and Axial Psoriatic Patients	nan	UNKNOWN
The Effect of Omalizumab on Responses to Cat Allergen Challenge	nan	COMPLETED
Correlation Between IgE Parameters and the Response to Omalizumab in Subjects With Severe Asthma	nan	WITHDRAWN

Related proteins — ESM-2 sequence neighbours (a FCGR3B binder may also engage these)

Protein	Name	Similarity
P08637	—	1.000	P08637 →
Q09TM2	—	1.000	Q09TM2 →
Q8SPW2	—	0.999	Q8SPW2 →
Q09TM4	—	0.998	Q09TM4 →
E2RP87	—	0.997	E2RP87 →
A3RFZ7	—	0.997	A3RFZ7 →
Q9N2I5	—	0.997	Q9N2I5 →
P27645	—	0.992	P27645 →
H0VDZ8	—	0.992	H0VDZ8 →
P79107	—	0.990	P79107 →
P08508	—	0.990	P08508 →
A0A0B4J1G0	—	0.989	A0A0B4J1G0 →
M3XWH1	—	0.989	M3XWH1 →
P12319	—	0.988	P12319 →
Q6XPU4	—	0.987	Q6XPU4 →
Q28942	—	0.987	Q28942 →
FCGR1A	High affinity immunoglobulin gamma Fc receptor I	0.986	landscape →
G1TR84	—	0.984	G1TR84 →
Q63203	—	0.984	Q63203 →
Q68SN8	—	0.983	Q68SN8 →
B6A8C7	—	0.983	B6A8C7 →
P31995	—	0.983	P31995 →
Q8SPV8	—	0.983	Q8SPV8 →
FCGR2A	Low affinity immunoglobulin gamma Fc region receptor II-a	0.981	landscape →
P31994	—	0.981	P31994 →
P26151	—	0.980	P26151 →
Q60513	—	0.980	Q60513 →
Q92637	—	0.979	Q92637 →
G1T7E7	—	0.979	G1T7E7 →
P0DTI4	—	0.978	P0DTI4 →